Latest Insider Transactions at Protara Therapeutics, Inc. (TARA)
This section provides a real-time view of insider transactions for Protara Therapeutics, Inc. (TARA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Protara Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Protara Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,300
+0.95%
|
$21,900
$3.8 P/Share
|
|
Sep 14
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
16,600
+1.22%
|
$49,800
$3.98 P/Share
|
|
Aug 11
2022
|
Jesse Shefferman CEO and President |
BUY
Open market or private purchase
|
Direct |
9,065
+1.02%
|
$27,195
$3.84 P/Share
|
|
Jul 16
2022
|
Hannah Fry VP, Controller |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+47.53%
|
-
|
|
Jul 15
2022
|
Blaine Davis Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,081
-19.74%
|
$15,243
$3.13 P/Share
|
|
Jul 01
2022
|
Jathin Bandari Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
682
-3.25%
|
$2,046
$3.22 P/Share
|
|
Jun 30
2022
|
Luke M Beshar |
BUY
Open market or private purchase
|
Direct |
10,000
+4.81%
|
$30,000
$3.1 P/Share
|
|
Apr 08
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,791
+47.66%
|
$31,164
$4.8 P/Share
|
|
Apr 07
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,345
+0.42%
|
$9,380
$4.74 P/Share
|
|
Mar 14
2022
|
Luke M Beshar |
BUY
Open market or private purchase
|
Direct |
10,000
+5.05%
|
$40,000
$4.25 P/Share
|
|
Mar 10
2022
|
Luke M Beshar |
BUY
Open market or private purchase
|
Direct |
10,000
+5.32%
|
$40,000
$4.46 P/Share
|
|
Jan 28
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
24,031
+1.96%
|
$96,124
$4.96 P/Share
|
|
Jan 10
2022
|
Jathin Bandari Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+50.0%
|
-
|
|
Jan 10
2022
|
Jesse Shefferman CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,080
-0.58%
|
$30,480
$6.27 P/Share
|
|
Jan 10
2022
|
Jacqueline Zummo Chf Scientific Operations Off |
SELL
Payment of exercise price or tax liability
|
Direct |
4,603
-5.51%
|
$27,618
$6.27 P/Share
|
|
Jan 03
2022
|
Blaine Davis Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,100
+47.51%
|
-
|
|
Jan 03
2022
|
Jesse Shefferman CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
42,300
+4.6%
|
-
|
|
Jan 03
2022
|
Jacqueline Zummo Chf Scientific Operations Off |
BUY
Grant, award, or other acquisition
|
Direct |
14,100
+14.44%
|
-
|
|
Dec 29
2021
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,500
+3.61%
|
$27,000
$6.98 P/Share
|
|
Dec 28
2021
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,091
+2.3%
|
$42,546
$6.36 P/Share
|
|
Dec 27
2021
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
36,700
+2.79%
|
$220,200
$6.53 P/Share
|
|
Dec 23
2021
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,300
+0.39%
|
$7,800
$6.6 P/Share
|
|
Dec 20
2021
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
703
+0.03%
|
$4,218
$6.49 P/Share
|
|
Dec 17
2021
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,790
+0.28%
|
$16,740
$6.6 P/Share
|
|
Dec 16
2021
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,563
+0.64%
|
$45,378
$6.41 P/Share
|
|
Nov 18
2021
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
15,206
+0.77%
|
$91,236
$6.98 P/Share
|
|
Nov 17
2021
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
9,118
+0.69%
|
$54,708
$6.98 P/Share
|
|
Nov 04
2021
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
6,557
+0.4%
|
$39,342
$6.5 P/Share
|
|
Jun 10
2021
|
Martin Sebastian Olivo Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
9,893
+30.05%
|
$98,930
$10.11 P/Share
|
|
Jan 11
2021
|
Jesse Shefferman CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,069
-0.6%
|
$106,449
$21.16 P/Share
|
|
Jan 11
2021
|
Jacqueline Zummo Chf Scientific Operations Off |
SELL
Payment of exercise price or tax liability
|
Direct |
4,653
-6.28%
|
$97,713
$21.16 P/Share
|
|
Sep 30
2020
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,000
+1.99%
|
$800,000
$16.0 P/Share
|
|
Sep 24
2020
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
300,000
+28.83%
|
$4,800,000
$16.87 P/Share
|
|
Nov 12
2019
|
Abingworth LLP |
BUY
Conversion of derivative security
|
Indirect |
126,645
+5.58%
|
$0
$0.99 P/Share
|
|
Nov 30
2017
|
James E Flynn Director |
SELL
Open market or private sale
|
Indirect |
110,557
-100.0%
|
$110,557
$1.75 P/Share
|
|
Nov 30
2017
|
James E Flynn Director |
BUY
Open market or private purchase
|
Indirect |
110,557
+35.9%
|
$110,557
$1.75 P/Share
|